The first quarter of 2026 marked a 10-year high for the quantity of public biotech acquisitions, with nine deals announced. While the total dollar value of $32 billion is typical, the high frequency indicates broad-based demand from pharma and a healthy, active M&A market that can recycle capital back into the industry.

The nature of biopharma M&A changed dramatically in a year. After a period with no deals over $5 billion, there are now seven or eight such transactions, reflecting a pivot by large pharma to acquire de-risked assets with large market potential to offset looming patent expirations.

Large pharmaceutical companies face losing up to 50% of their revenues by 2030 due to the largest patent expiration wave in history. To survive, they will be forced to acquire innovation from the biotechnology sector, fueling a sustained M&A cycle for years to come.

After years of focusing on de-risked late-stage products, the M&A market is showing a renewed appetite for risk. Recent large deals for early-stage and platform companies signal a return to an era where buyers gamble on foundational science.

Jefferies' Philip Ross argues that while large pharmaceutical companies have ample cash ("firepower"), the true constraint is their P&L capacity. Integrating and funding a new development asset requires making difficult internal budget cuts, as every dollar is already accounted for, limiting their ability to pursue deals that don't self-fund.

Despite shedding over 22,000 jobs, large pharmaceutical companies are aggressively investing in external assets. This counterintuitive trend is driven by the urgent need to fill revenue gaps from a looming $300 billion patent cliff, signaling a major strategic shift from internal R&D to external innovation acquisition.

Big pharma is heavily investing in AI-driven drug discovery platforms. Deals like Sanofi with Irindale Labs, Eli Lilly with Nimbus, and AstraZeneca's acquisition of Modelo AI highlight a strategic shift towards acquiring foundational AI capabilities for long-term pipeline generation, rather than just licensing individual preclinical assets.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.

In a major strategic shift, large pharmaceutical companies are increasingly sourcing their M&A pipeline from China. Chinese assets now account for 30-40% of Big Pharma's early-stage acquisitions, up from single digits just a few years ago, primarily because they are significantly cheaper than US or European equivalents.